X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the terms of the agreement, BioNova has the option to obtain exclusive rights to develop and commercialize STRO-001 in Greater China. Sutro will provide STRO-001 to BioNova under appropriate clinical and commercial supply service agreements.
Lead Product(s): STRO-001
Therapeutic Area: Oncology Product Name: STRO-001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioNova Pharmaceuticals
Deal Size: $204.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration October 12, 2021
Details:
Net proceeds from the proposed offering, together with its existing cash, cash equivalents and marketable securities, to fund the continued clinical development of STRO-001 and STRO-002 and the remainder to fund the further development of its technology platform.
Lead Product(s): STRO-001
Therapeutic Area: Oncology Product Name: STRO-001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cowen
Deal Size: $126.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 08, 2020
Details:
The STRO-001 Phase1 clinical trial is currently in dose-escalation, enrolling patients with non-Hodgkin lymphoma and multiple myeloma.
Lead Product(s): STRO-001
Therapeutic Area: Oncology Product Name: STRO-001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
Sutro intends to use the net proceeds from the proposed offering to fund the continued clinical development of STRO-001 and STRO-002.
Lead Product(s): STRO-001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Baillie Gifford
Deal Size: $98.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 14, 2020
Details:
Sutro intends to use the net proceeds together with its existing cash, cash equivalents and marketable securities, to fund the continued clinical development of STRO-001 and STRO-002.
Lead Product(s): STRO-001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cowen
Deal Size: $85.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
